Drugs Affecting Blood and Blood Formation Practice Questions

Q: Filgrastim is used in treatment of:

Neutropenia. ***Neutropenia*** - **Filgrastim** is a **granulocyte colony-stimulating factor (G-CSF)**, which stimulates the production and release of neutrophils from the bone marrow. - It is primarily used to treat or prevent **neutropenia**, a condition characterized by abnormally low levels of neutrophils, often seen in cancer patients undergoing chemotherapy. *Anemia* - **Anemia** is a condition characterized by a deficiency of red blood cells or hemoglobin. - While red blood cells are also produced in the bone marrow, G-CSFs like filgrastim do not directly stimulate **erythropoiesis** (red blood cell production). *Malaria* - **Malaria** is a parasitic disease transmitted by mosquitoes, affecting red blood cells and other organs. - Treatment for malaria involves **antimalarial drugs** that target the parasite, not bone marrow stimulants like filgrastim. *Filarial* - **Filariasis** is a parasitic disease caused by roundworms, typically transmitted by mosquitoes or black flies. - Treatment involves **anthelmintic drugs** to kill the parasites and manage symptoms, not filgrastim, which targets neutrophil production.

Q: What type of anticoagulant is Apixaban?

Direct Xa inhibitor. ***Direct Xa inhibitor*** - **Apixaban** belongs to a class of anticoagulants known as **direct oral anticoagulants (DOACs)**. - It directly inhibits **Factor Xa**, preventing the conversion of **prothrombin to thrombin** and thereby blocking the coagulation cascade. *Antithrombin inhibitor* - **Antithrombin inhibitors** like unfractionated heparin and low molecular weight heparins work by enhancing the activity of the natural anticoagulant **antithrombin**. - Apixaban's mechanism of action is independent of antithrombin. *Vitamin K antagonist* - **Vitamin K antagonists** such as **warfarin** interfere with the synthesis of **vitamin K-dependent clotting factors** (II, VII, IX, X) in the liver. - Apixaban does not affect vitamin K metabolism. *Clotting Factor XII* - **Factor XII** (Hageman factor) is involved in the intrinsic pathway of coagulation. - Apixaban specifically targets **Factor Xa**, not Factor XII.

Q: What is the primary function of PGI2?

Inhibits platelet aggregation. ***Inhibits platelet aggregation*** - **PGI2 (prostacyclin)** is a potent inhibitor of **platelet aggregation** by increasing cAMP in platelets, preventing thrombus formation. - In the context of **cardiovascular pharmacology** and **hemostasis**, PGI2's antiplatelet action is clinically emphasized as its **primary therapeutic target**, especially when contrasted with **thromboxane A2 (TXA2)**, which promotes platelet aggregation. - PGI2 is often described as the body's **endogenous antiplatelet agent**, making this its most clinically significant function. - It also causes vasodilation (see below), but when discussing PGI2's "primary function" in most pharmacology contexts, the **antiplatelet effect** is highlighted. *Is a vasodilator* - **TRUE but incomplete**: PGI2 is indeed a potent **vasodilator** through smooth muscle relaxation. - However, many substances cause vasodilation, whereas PGI2's unique and clinically defining role in the **COX pathway** is its opposition to platelet aggregation. - Both functions are physiologically important and work synergistically, but in pharmacological classification, the **antiplatelet action** is typically considered the defining characteristic. *Is pyrogenic* - **Incorrect**: PGI2 does not cause fever. - **PGE2** (not PGI2) is the prostaglandin primarily associated with fever induction (pyrogenic effects). *None of the options* - Incorrect because **inhibits platelet aggregation** accurately describes PGI2's primary pharmacological function. - PGI2 has well-established roles in hemostasis and vascular biology.

Q: Which drug requires continuous monitoring of prothrombin time?

Coumadin. ***Coumadin*** - **Coumadin (warfarin)** is an oral anticoagulant that inhibits vitamin K epoxide reductase, thereby reducing the synthesis of **vitamin K-dependent clotting factors** (II, VII, IX, X). - Its narrow therapeutic index and significant variability in dosage requirements necessitate continuous monitoring of the **prothrombin time (PT)**, reported as the **International Normalized Ratio (INR)**, to ensure efficacy and prevent bleeding complications. *Aspirin* - **Aspirin** is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1), preventing the synthesis of thromboxane A2, which is crucial for platelet aggregation. - It does not directly affect the coagulation cascade or prothrombin time; its antiplatelet effects are typically monitored by patient response and bleeding time, though routine monitoring is not usually required for standard antiplatelet therapy. *Digoxin* - **Digoxin** is a cardiac glycoside used to treat heart failure and atrial fibrillation by increasing myocardial contractility and slowing AV nodal conduction. - Its therapeutic effects and potential toxicity are monitored through serum digoxin levels, electrolyte balance (especially potassium), and electrocardiograms for signs of dysrhythmias, not by prothrombin time. *Lepirudin* - **Lepirudin** is a direct thrombin inhibitor (DTI) used in patients with heparin-induced thrombocytopenia (HIT). - Its anticoagulant effect is typically monitored using the **activated partial thromboplastin time (aPTT)**, not prothrombin time.

Q: What is the primary treatment indication of folic acid?

Treatment of megaloblastic anemia. ***Treatment of megaloblastic anemia*** - Folic acid is essential for **DNA synthesis** and cell division, and its deficiency leads to impaired red blood cell maturation, causing **megaloblastic anemia**. - Supplementation with folic acid effectively reverses the hematological abnormalities in **folate-deficient megaloblastic anemia**. *Prevention of neural tube defects in pregnancy* - While folic acid is crucial for preventing **neural tube defects** (NTDs), this is a **prophylactic** rather than a primary therapeutic use. - The focus of this question is on the *primary therapeutic* use, implying treatment of an existing condition. *Management of hemoglobinopathies* - Hemoglobinopathies like **sickle cell anemia** or **thalassemia** are genetic disorders affecting hemoglobin structure or production, not primarily due to folic acid deficiency. - Folic acid may be given to these patients to support increased red blood cell turnover, but it does not address the underlying genetic defect. *None of the above* - This option is incorrect because folic acid has a clear primary therapeutic role in treating **megaloblastic anemia**.

Q: All of the following are medical uses of erythropoietin except?

Megaloblastic Anemia. ***Megaloblastic Anemia*** - Megaloblastic anemia is caused by **vitamin B12 or folate deficiency**, which impairs DNA synthesis and leads to the production of large, immature red blood cells. - Treatment involves supplementing the deficient vitamin (B12 or folate), as erythropoietin does not address the underlying cause of impaired red blood cell maturation. *Treatment of anaemia associated with renal disease* - **Erythropoietin** is primarily produced by the kidneys, and chronic kidney disease often leads to decreased erythropoietin production, resulting in anemia. - Administering exogenous erythropoietin stimulates red blood cell production, making it a critical treatment for **anemia of chronic kidney disease**. *Chemotherapy induced anemia* - Chemotherapy can suppress bone marrow function, leading to **decreased red blood cell production** and subsequent anemia. - Erythropoietin-stimulating agents can be used to mitigate this side effect by **stimulating erythropoiesis** in the bone marrow. *Specific cases of anemia associated with Crohn's disease.* - Anemia in Crohn's disease can have multiple causes, including iron deficiency from blood loss, malabsorption of vitamins, and **anemia of chronic disease**. - Erythropoietin may be considered in cases where the anemia is primarily due to **inflammation-induced suppression of erythropoiesis** or decreased erythropoietin response, particularly if other treatments are ineffective.

Q: What is the mechanism of action of ticagrelor?

Reversible inhibition of ADP action. ***Reversible inhibition of ADP action*** - **Ticagrelor** is a **P2Y12 receptor antagonist** that works by preventing ADP from binding to its receptor on platelets [2]. - This binding is **reversible**, meaning ticagrelor can dissociate from the receptor, allowing for some recovery of platelet function over time [2]. *Irreversible inhibition of ADP action* - **Clopidogrel** and **prasugrel** are examples of **irreversible P2Y12 inhibitors**, forming a permanent bond with the receptor [2]. - Irreversible inhibition leads to a longer duration of platelet inhibition, as new platelets must be generated for function to return [2]. *Reversible inhibition of GPIIb/IIIa* - **GPIIb/IIIa inhibitors** like **eptifibatide** and **tirofiban** block the final common pathway of platelet aggregation by preventing fibrinogen binding [1]. - While their action is reversible, they target a *different* mechanism than ticagrelor. *Irreversible inhibition of GPIIb/IIIa* - **Abciximab** is a GPIIb/IIIa inhibitor that binds **irreversibly** (or with very slow dissociation) to the receptor [1]. - Unlike reversible GPIIb/IIIa inhibitors, abciximab is a monoclonal antibody with a prolonged antiplatelet effect [1]. - This is still an incorrect answer as ticagrelor targets the P2Y12 receptor, not GPIIb/IIIa.

Q: Ximelagatran is used as ?

Anticoagulant. ***Anticoagulant*** - Ximelagatran is a **direct thrombin inhibitor**, meaning it directly blocks the action of thrombin, a key enzyme in the coagulation cascade. - By inhibiting thrombin, it prevents the formation of **fibrin clots**, thus acting as an anticoagulant. *Platelet inhibitor* - **Platelet inhibitors** prevent platelets from clumping together to form a clot, often by targeting pathways like ADP receptors or COX-1 enzyme. - Examples include **aspirin** and **clopidogrel**, which have different mechanisms of action than Ximelagatran. *Clot buster* - **Clot busters** are also known as thrombolytic agents, which actively dissolve existing blood clots. - They work by activating **plasminogen** to produce plasmin, an enzyme that breaks down fibrin. *Fibrinolytic* - **Fibrinolytics** are a class of drugs that enhance **fibrinolysis**, the natural process of breaking down blood clots. - **Thrombolytics** are a subset of fibrinolytic drugs used therapeutically to dissolve clots.

Q: Which of the following anticoagulants is given orally?

Rivaroxaban. ***Rivaroxaban*** - Rivaroxaban is a **direct oral anticoagulant (DOAC)** that specifically inhibits **Factor Xa**. - It is administered orally and does not require routine coagulation monitoring. *Argatraban* - Argatroban is a **direct thrombin inhibitor (DTI)** primarily used intravenously, especially in patients with **heparin-induced thrombocytopenia (HIT)**. - It is not an orally administered anticoagulant. *Alteplase* - Alteplase is a **thrombolytic agent** (clot buster), not an anticoagulant, that works by converting **plasminogen to plasmin**. - It is administered intravenously to dissolve existing clots. *Fondaparinux* - Fondaparinux is a **synthetic pentasaccharide** that selectively inhibits **Factor Xa** by binding to antithrombin. - It is administered **subcutaneously**, not orally.

Question 1

Filgrastim is used in treatment of:

Accepted Answer

Neutropenia

Answer

Anemia

Answer

Malaria

Answer

Filariasis

Question 2

What type of anticoagulant is Apixaban?

Accepted Answer

Direct Xa inhibitor

Answer

Antithrombin inhibitor

Answer

Vitamin K antagonist

Answer

Factor XII inhibitor

Question 3

What is the primary function of PGI2?

Accepted Answer

Inhibits platelet aggregation

Answer

Is a vasodilator

Answer

Is pyrogenic

Answer

None of the options

Question 4

Which drug requires continuous monitoring of prothrombin time?

Accepted Answer

Coumadin

Answer

Digoxin

Answer

Aspirin

Answer

Lepirudin

Question 5

What is the primary treatment indication of folic acid?

Accepted Answer

Treatment of megaloblastic anemia

Answer

Prevention of neural tube defects in pregnancy

Answer

Management of hemoglobinopathies

Answer

None of the above

Question 6

All of the following are medical uses of erythropoietin except?

Accepted Answer

Megaloblastic Anemia

Answer

Treatment of anaemia associated with renal disease

Answer

Chemotherapy induced anemia

Answer

Specific cases of anemia associated with Crohn's disease.

Question 7

Which of the following statements best describes the underlying mechanism of heparin-induced thrombocytopenia?

Accepted Answer

Antibodies are formed against heparin-platelet factor 4 complexes.

Answer

Low molecular weight heparin can also cause heparin-induced thrombocytopenia.

Answer

Vitamin K is not an antidote for heparin-induced thrombocytopenia.

Answer

Heparin-induced thrombocytopenia can occur after several days of heparin therapy.

Question 8

What is the mechanism of action of ticagrelor?

Accepted Answer

Reversible inhibition of ADP action

Answer

Irreversible inhibition of ADP action

Answer

Reversible inhibition of GPIIb/IIIa

Answer

Irreversible inhibition of GPIIb/IIIa

Question 9

Ximelagatran is used as ?

Accepted Answer

Anticoagulant

Answer

Fibrinolytic

Answer

Platelet inhibitor

Answer

Clot buster

Question 10

Which of the following anticoagulants is given orally?

Accepted Answer

Rivaroxaban

Answer

Argatraban

Answer

Alteplase

Answer

Fondaparinux

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?